What we have achieved

2000Volunteers recruited
250Completed trials since 1996
70Investigator Initiated Trials completed
180Industry Sponsored Trials completed

Ongoing clinical trials in IMU

Phase 3 haematology study to evaluate the safety and efficacy of ALXN1210 compared to eculizumab

Phase 3 haematology study to evaluate the safety and efficacy of ALXN1210 compared to eculizumabStudy Details This is a Phase 3, open-label, randomized, active-controlled, multicenter study to evaluate the safety and efficacy of ALXN1210 versus eculizumab administered by intravenous (IV) infusion to adult patients with PNH who are naïve to complement inhibitor treatment. Protocol Number …

Phase 3 haematology study to evaluate the safety and efficacy of ALXN1210 compared to eculizumabRead More »

Phase 3 Anemia Study in CKD to evaluate the safety and efficacy of daprodustat compared to darbepoetin alfa (ASCEND-ND)

A phase 3 randomized, open-label (sponsor-blind), activecontrolled, parallel-group, multi-center, event driven study in non-dialysis subjects with anemia associated with chronic kidney disease to evaluate the safety and efficacy of daprodustat compared to darbepoetin alfa.

Anemia Studies in CKD: Erythropoiesis via a Novel PHI Daprodustat-Non-Dialysis (ASCEND-ND)

Phase 3 Allergy study to investigate the effect of a partially hydrolysed infant formula with added synbiotics (Maestro)

A randomised, double-blind, controlled, parallel-group, multi-country study to investigate the effect of a partially hydrolysed infant formula with added synbiotics on the development of allergic manifestations in infants at high risk of developing allergy. (Maestro)

Volunteers

Be a hero to others today!

Be part of a journey to discover new therapies to improve the future of healthcare.

Partners

Interested to work together with us?

Collaborate with IMU to discover better treatments for a better tomorrow.